Figure 2.

Generation of CD19-NK-92 and CD138-NK-92 cells and analysis of surface antigens in target cancer cells. (a) NK-92 cells were subjected to multiple rounds of lentiviral transduction of anti-CD19-CAR or anti-CD138-CAR and sequential FACS enrichment using anti-F(ab′)2 antibody to generate highly expressed, stable CD19-NK-92 and CD138-NK-92 cells. (b) CAR expression in enriched CD19-NK-92 (left) and CD138-NK-92 (right) cells, as evaluated by flow cytometry based on its binding activity to His tag-rhCD19 or His tag-rhCD138. (c) Flow cytometric analysis of surface CD19 and CD138 expression in human CML-derived K562, human ALL-derived REH, human BL-derived Raji, and human MM-derived H929 and RPMI-8226 cells.